

Table SI. Clinical findings for the 45 localized injection-site toxic erythema of chemotherapy cases at our department

Clinical findings	
Drug ⁿ (%)	
Vinorelbine	14 (31)
Docetaxel	15 (33)
5-fluoruracil	7 (16)
Others	9 (20)
Clinical features ⁿ (%)	
Local erythema multiforme-like	18 (40)
Linear supravenous erythema	14 (31)
Fixed drug eruption-like	13 (29)
Location ⁿ (%)	
Forearm	21 (47)
Dorsum of the hand	17 (38)
Cubital	6 (13)
Chest	1 (2)
Recurrence ⁿ (%)	
Yes	7 (16)
No	38 (84)
Number of cycles, <i>n</i>	
Median (range)	15 (1–16)

Table SII. Histopathological findings

Histopathological finding	Main features (of each histopathological finding)	Characteristics (when applicable)	%
Inflammatory infiltrate	Intensity	Intense	25
		Mild	25
		Scarce	50
	Distribution	Perivascular, interstitial and lichenoid Interstitial and lichenoid Lichenoid	16 33 50
Epidermal involvement	Hydropic degeneration	Limited	75
	Keratinocyte necrosis	Intense	25
		Scattered	33
Epidermis maturation changes	Mitotic retention images Nuclear atypia Dyskeratosis	Abundant	33
		Full thickness necrosis	33
			25
Eccrine squamous syringometaplasia			40
			50
			41

Table III. Previously reported cases of localized injection-site toxic erythema of chemotherapy (TEC) (localized epidermal necrolysis; EN) available in the literature

Reference	Cases, n	Description	Involved cytostatic therapy	Onset time	Location	Clinical appearance	Histopathology	Resolution/Other
Chan and Lin (15).	1	Serpentine supravenous pigmentation	Doxorubicin + cyclophosphamide + 5-FU	1 day	Left arm	EM	Hyperkeratotic epidermis, vacuolization of the basal layer, necrotic keratinocytes, and lymphocytic infiltrate (often perivascular)	Resolution in 4 months. Erythematous phase preceding hyperpigmentation.
Ghosh et al. (12).	1	Docetaxel-induced supravenous serpentine dermatitis	Docetaxel	1 day	Right arm	PSE	Basket-weave pattern of hyperkeratosis, spongiosis with lymphocytic and neutrophilic exocytosis, irregular acanthosis, focal basal cell degeneration, upper dermal band-like as well as perivascular lympho-mononuclear infiltrates, and papillary dermal oedema	Practically solved in 4 weeks with mometasone furoate cream tid.
Aydogan (S1)	1	Persistent serpentine supravenous hyperpigmented eruption	Cisplatin + gemcitabine + Docetaxel	2 days	Right arm	PSE	Hyperkeratosis, vacuolization of the basal Resolution in 6 months	
Rao and Balachandran (S2)	1	Persistent supravenous eruption	Bortezomib + CHOP	8 hours	Right arm, Left arm	PSE	Interface dermatitis with isolated necrotic keratinocytes, oedema of the underlying papillary dermis, and a superficial perivascular inflammatory infiltrate	
Mataix et al. (S3)	1	Persistent supravenous erythematous eruption	5-FU	4 days	Both arms	PSE	Interface dermatitis with vacuolization of the basal cells and necrotic keratinocytes.	Residual pigmentation
Vukelja et al. (S4)	1	Serpentine supravenous pigmentation	5-FU + Oxaliplatin	1 day	Right arm	PSE	Interface dermatitis with vacuolization of the basal cells and necrotic keratinocytes.	Gradual vanishing in 3 months
Arias et al. (8)	1	EM-like	Vinblastin	1 day	Forearm	EM	–	Scaliness in 1 week.
Nigro and Hsu (S5)	1	Supravenous serpentine scaling	Actinomycin D + Vincristine	7 days	Arm	PSE	Vacuolization, lymphocytoclastic vasculitis	Persistent at 5 months
Chen et al. (S6)	2	Linear supravenous papules	Bromodeoxyuridine	NR	2 days	Forearm	PSE	NR
Zimmerman et al. (S7)	3	Isolated erythrodysthesia lesion	Docetaxel	1, 2, 3	NR	Forearm	FDE	Peeling in 1 week
Fine and Breathnach (S8)	3	Local reactions	Paclitaxel	–	–	PSE	–	–
Hirai et al. (S9)	1	EM-like	Docetaxel	1	7 days	Forearm	EM	Ulceration
Dorr and Jones (S10).	4	Absent infiltration	Vindesine	NR	1 days	Both hands	FDE	Peeling in 2 weeks
Spencer (S11)	1	EM-like	Mitomycin + 5-FU	3	1 days	Both forearms	EM	
Koehn and Balizet (S12)	1	Local cutaneous reaction	Dacarbazine	4	1 days	Forearm	EM	Basal vacuolar degeneration, necrotic keratinocytes
Misery et al. (S13)	1	Local EN	Vinorelbine	2	2 days	Forearm	EM	Basal vacuolar degeneration, necrotic keratinocytes
Chu et al. (10).	4	Located erythrodysthesia	Docetaxel	1,2,3	7–14 days	Forearm – hand's dorsum	FDE (3) PSE (1)	Peeling in 3 weeks
Correia et al. (S14)	2	Located erythrodysthesia	Docetaxel	NR	5–8 days	Forearm	–	Residual pigmentation.
Suvriya et al. (S15)	1	Persistent supravenous hyperpigmented eruption	5-FU	1 (left forearm) 2 (right forearm)	2 days	Both forearms	PSE	Scaliness in 6 weeks
Das et al. (S16)	1	Supravenous serpentine dermatitis	Docetaxel	1	2 days	Lower limb	PSE	Significant decrease in hyperpigmentation at the end of fourth month
							NR	
							NR	
							NR	
							NR	

Table III. Contd.

Reference	Cases, n	Description	Involved cytostatic cycle	Chemo-therapy time	Onset	Location	Clinical appearance	Histopathology	Resolution/Other
Akyurek et al. (S17)	1	Serpentine supravenous hyperpigmentation	Carboplatin +Vinorelbine	1	14 days	Left forearm	PSE	Loss of superficial epidermis, perivascular Amelioration of erythematous and bullous lesions within a few days. Hyperpigmented tracts remained	
Jamalpur et al. (S18)	1	Serpentine supravenous hyperpigmentation	Docetaxel	–	7 days	Right forearm	PSE	–	–

EM: erythema multiforme; PSE: Persistent serpentine supravenous hyperpigmentation/eruption; FDE: fixed drug eruption; 5-FU: 5-fluorouracil; CHOP: cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisone; NR: not reported.

SUPPLEMENTARY REFERENCES

S1. Aydogan I. Persistent serpentine supravenous hyperpigmentation associated with docetaxel. *J Eur Acad Dermatol Venereol* 2005; 345-347.

S2. Rao R, Balachandran C. Serpentine supravenous pigmentatio. A rare vasculo-cutaneous effect induced by systemic 5-fluorouracil. *Indian J Dermatol Venereol Leprol* 2010; 76: 714-715.

S3. Mataix J, Bettlich I, Palmero F, Romero A. Persistent supravenous eruption induced by intravenous bortezomib therapy. *Br J Dermatol* 2008; 158: 863-864.

S4. Vukelja SJ, Bonner MW, McCollough M, Cobin PW, Gaulé DA, Fanucchi PJ, et al. Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil. *J Am Acad Dermatol* 1991; 25: 905-908.

S5. Nigro MG, Hsu S. Bleomycin-induced flagella pigmentation. *Cutis* 2001; 68: 285-286.

S6. Chen G-Y, Lee Y-Y, Chen W-C. Sclerotic and retracted supravenous hyperpigmentation associated with combination chemotherapy for metastatic breast carcinoma. *Br J Dermatol* 2005; 152: 1383-1385.

S7. Zimmerman GC, Keeling JH, Burns HA, Cook G, Irvin R, Kuhn J, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. *Arch Dermatol* 1995; 131: 202-206.

S8. Fine JD, Breathnach SM. Distinctive eruption characterized by linear supravenous papules and erythroderma following broxuridine (bromodeoxyuridine) therapy and radiotherapy. *Arch Dermatol* 1986; 122: 199-200.

S9. Hirai K, Ishiko O, Nakajima S, Kanazawa Y, Oiso N, et al. Local erythematous dermatitis after intravenous docetaxel. *Gynecol Obstet Invest* 2002; 53: 118-120.

S10. Dorr RI, Jones SE. Inapparent infiltrations associated with vindesine administration. *Med Pediatr Oncol* 1979; 6: 285-288.

S11. Spencer HJ. Local erythema multiforme-like drug reaction following intravenous mitomycin C and 5-fluorouracil. *J Surg Oncol* 1984; 26: 47-50.

S12. Koehn GG, Balizet LB. Unusual local cutaneous reaction to dacarbazine. *Arch Dermatol* 1982; 118:1018-1019.

S13. Misery L, Perrut JL, Vergnon JM, Emonot A, Claudio A. Nécrose épidermique localisée après injection intraveineuse de vinorelbine. *Presse Med* 1992; 21: 2153.

S14. Correia O, Azevedo C, Pinto Ferreira E, Braga Cruz F, Polonia J. Nail changes secondary to docetaxel (Taxotere). *Dermatology* 1999; 198: 288-290.

S15. Suvriya S, Agrawal A, Parikh A, Parikh A. 5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. *BMJ Case Rep* 2014; 2014: bcr2014206793.

S16. Das A, Kumar D, Mohanty S, Mondal A, Chowdhury S, Bandyopadhyay D. Serpentine supravenous hyperpigmentation induced by docetaxel. *Indian J Dermatol Venereol Leprol* 2015; 81: 434.

S17. Akyurek FT, Sarı N, Uğurluoglu C, Kurtipek GS. Serpentine supravenous hyperpigmentation related to carboplatin and vinorelbine chemotherapy: a case report. *Dermatol Ther* 2019; 32: e12981.

S18. Jamalpur I, Mogili HR, Koratala A. Serpentine supravenous hyperpigmentation. *Clin Case Reports* 2017; 5: 1546-1547.